DOCSLIB.ORG

G Protein-Coupled Receptors As Targets for Approved Drugs: How Many Targets and How Many Drugs? S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
G Protein-Coupled Receptors As Targets for Approved Drugs: How Many Targets and How Many Drugs? S Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2018/01/03/mol.117.111062.DC1 1521-0111/93/4/251–258$35.00 https://doi.org/10.1124/mol.117.111062 MOLECULAR PHARMACOLOGY Mol Pharmacol 93:251–258, April 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics MINIREVIEW—AXELROD SYMPOSIUM 2017 G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? s Krishna Sriram and Paul A. Insel Departments of Pharmacology (K.S., P.A.I.) and Medicine (P.A.I.), University of California San Diego, La Jolla, California Downloaded from Received November 8, 2017; accepted December 21, 2017 ABSTRACT Estimates vary regarding the number of G protein-coupled drugs target GPCRs. GPCRs and GPCR-related proteins, i.e., receptors (GPCRs), the largest family of membrane receptors those upstream of or downstream from GPCRs, represent molpharm.aspetjournals.org that are targeted by approved drugs, and the number of such ∼17% of all protein targets for approved drugs, with GPCRs drugs that target GPCRs. We review current knowledge themselves accounting for ∼12%. As such, GPCRs consti- regarding GPCRs as drug targets by integrating data from tute the largest family of proteins targeted by approved public databases (ChEMBL, Guide to PHARMACOLOGY, and drugs. Drugs that currently target GPCRs and GPCR- DrugBank) and from the Broad Institute Drug Repurposing related proteins are primarily small molecules and peptides. Hub. To account for discrepancies among these sources, we Since ∼100 of the ∼360 human endo-GPCRs (other than curated a list of GPCRs currently targeted by approved drugs. olfactory, taste, and visual GPCRs) are orphan receptors As of November 2017, 134 GPCRs are targets for drugs (lacking known physiologic agonists), the number of GPCR approved in the United States or European Union; 128 GPCRs targets, the number of GPCR-targeted drugs, and perhaps are targets for drugs listed in the Food and Drug Administra- the types of drugs will likely increase, thus further expanding at ASPET Journals on September 27, 2021 tion Orange Book. We estimate that ∼700 approved drugs this GPCR repertoire and the many roles of GPCR drugs in target GPCRs, implying that approximately 35% of approved therapeutics. Introduction clarify this ambiguity, we reviewed information from three majorpublicdatabases(seeMaterials and Methods). We report Based on their canonical structure, G protein-coupled recep- here the results of this analysis regarding the identity and tors (GPCRs), which are sometimes termed heptahelical or number of GPCR targets and drugs that target those GPCRs, as 7-transmembrane receptors, are the largest family of mem- well as GPCR-related proteins upstream (e.g., ligands) and brane receptors in humans and numerous other species. In downstream (e.g., phosphodiesterases [PDEs] that degrade addition, GPCRs are considered the largest family of targets for cAMP). In addition, we provide information about the types of approved drugs (Allen and Roth, 2011; Rask-Andersen et al., chemical entities that are GPCR-directed therapeutics and 2014; Santos et al., 2017). Numerous factors contribute to the identify inconsistencies among the databases regarding GPCR wide utility of GPCR-targeted drugs, including their drugg- targets and drugs directed at those targets. ability, interaction with numerous types of chemical entities, and expression in the plasma membrane, which facilitates Materials and Methods molecular interactions in the extracellular milieu. Scientific We assessed information regarding approved drugs, drug targets, articles, grant applications, and lectures that describe findings and if available ligand-target interactions from three online data- related to GPCRs often note the therapeutic utility of GPCRs bases: ChEMBL (Bento et al., 2014), DrugBank (Wishart et al., 2007), but differ widely in estimates of their contribution as targets for and the International Union of Basic and Clinical Pharmacology/BPS approved drugs, which generally range from ∼20% to .50%. To (British Pharmacological Society) Guide to PHARMACOLOGY (GtoPdb) (Southan et al., 2016; Alexander et al., 2017). We consoli- This work was supported by the American Society of Pharmacology and dated data from each source into tables that relate the drugs approved Experimental Therapeutics (ASPET) David Lehr Award, and by grants from the for use in humans to their targets. We obtained a list of all annotated National Institutes of Health (R21AG52914, R21AG053568) and the Department human GPCRs (excluding olfactory and vision receptors) from GtoPdb of Defense (W81XWH-14-1-0372), and a contract with Bristol-Myers Squibb. (Alexander et al., 2017); the genes/proteins on this list were then https://doi.org/10.1124/mol.117.111062. s This article has supplemental material available at molpharm. queried from different sources to identify GPCRs that are drug aspetjournals.org. targets. Approved drugs were cross-checked against those listed by ABBREVIATIONS: BPS, British Pharmacological Society; EMA, European Medicines Agency; FDA, Food and Drug Administration; GPCR, G protein-coupled receptor; GtoPdb, Guide to PHARMACOLOGY; HRH1, histamine H1 receptor; PDE, phosphodiesterase. 251 252 Sriram and Insel the Food and Drug Administration (FDA) (fda.gov) and European Numerous approved drugs are physiological agonists for Medicines Agency (EMA) (ema.europa.eu/ema/). As an additional GPCRs (for example, epinephrine [at multiple adrenergic source, we used data from the Broad Institute Drug Repurposing receptors] and numerous peptide hormones). Entries in bold Hub (Corsello et al., 2017), which employed high-throughput screen- in Table 1 indicate GPCRs considered primary targets for the ing to characterize drug-target interactions of approved drugs, natural listed drug, based on affinity and/or functional response (in the products, and nutraceuticals along with other entities. majority of cases, both). Entries not in bold indicate GPCRs Our analysis yielded a list of currently druggable GPCRs and the drugs that target them. Because of possible database errors in targeted by approved drugs but for which such an interaction downloadable material, as well as ambiguity of ligand-target interac- is not likely a primary aspect of the intended therapeutic use tions in certain sources, we manually curated each druggable GPCR to of such drugs. Such GPCR-ligand interactions may contribute verify pharmacological interaction of the approved drugs. The primary to side effects. In a number of cases, data are ambiguous sources used for crosschecking the data were the aforementioned regarding precisely which receptors are responsible for medi- databases, plus the Drug Gene Interaction Database (dgidb.org; Cotto ating the therapeutic efficacy of GPCR-targeted drugs. In such et al, 2017) and GeneCards (genecards.org; Rebhan et al., 1998), along cases, if pharmacological data implicate a strong GPCR-drug with primary sources cited within these databases. affinity, we list GPCR-drug pairs in bold. An example is the The resulting list of GPCRs targeted by approved drugs (Table 1) melanocortin receptor family (MC1R–MC5R), which may includes an example of an approved drug that targets each GPCR. mediate a number of therapeutic effects of corticotropin/ Certain GPCRs (for example, histamine H1) are the targets for multiple Downloaded from drugs. Supplemental Table 2 lists all such GPCR-targeted drugs. In adrenocorticotropin (ACTH; Gong, 2014). Similarly, the pre- some cases, we considered families of GPCRs as targets for the same cise importance of each of the somatostatin receptors as drugs (e.g., multiple P2Y receptors are targets for suramin and multiple targets for pasireotide and lanreotide is incompletely un- S1P receptors as targets for fingolimod). For such examples, we list the derstood (e.g., Feelders et al., 2012). In total, we thus list GPCRs and approved drugs with the caveat that some of the drug- 98 GPCRs that are thought to mediate therapeutic effects of GPCR interactions are not well defined. In certain cases (e.g., suramin), approved drugs, with an additional 36 GPCRs that interact the approval status of a drug is unclear; we provide details for such with approved drugs and may contribute to therapeutic effects molpharm.aspetjournals.org drugs in Table 1 and the accompanying legend. or side effects. We excluded multiple GPCRs as primary We thus assembled an integrated list of approved drugs that target targets for molecules with affinity for multiple members GPCRs by combining data from the previously noted databases within one or more GPCR families. As examples, caffeine (ChEMBL, GtoPdb, and DrugBank) and the Broad Drug Repurposing Hub. Due to difficulties in cross-referencing information among the and theophylline bind multiple adenosine receptors including databases (since common identifiers such as Chemical Abstracts ADORA2B, but we do not consider that receptor to be a Service numbers are not provided for drugs listed by all sources), we primary target for any approved drugs. Our rationale is generated lists of GPCR-related drugs using drug names. We consid- similar for suramin, which binds multiple P2Y receptors. ered drugs with multiple derivatives (such as different salts) as Different databases/sources identify differing numbers and duplicates in counting GPCR-related drugs and evaluating over- identities of GPCRs that are targets of approved drugs. at ASPET Journals on September
Load more

Recommended publications
  • Functional Selectivity and Partial Efficacy at the Monoamine Transporters: a Unified Model of Allosteric Modulation and Amphetamine-Induced Substrate Release
    1521-0111/95/3/303–312$35.00 https://doi.org/10.1124/mol.118.114793 MOLECULAR PHARMACOLOGY Mol Pharmacol 95:303–312, March 2019 Copyright ª 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. MINIREVIEW Functional Selectivity and Partial Efficacy at the Monoamine Transporters: A Unified Model of Allosteric Modulation and Amphetamine-Induced Substrate Release Peter S. Hasenhuetl,1,2 Shreyas Bhat,2 Michael Freissmuth, and Walter Sandtner Downloaded from Institute of Pharmacology, Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria Received October 2, 2018; accepted December 13, 2018 ABSTRACT molpharm.aspetjournals.org All clinically approved drugs targeting the plasmalemmal trans- allosteric inhibition and stimulation of MATs, which can be porters for dopamine, norepinephrine, and serotonin act either functionally selective for either substrate uptake or amphetamine- as competitive uptake inhibitors or as amphetamine-like releas- induced release. These concepts are integrated into a parsimonious ers. Monoamine transporter (MAT) ligands that allosterically kinetic framework, which relies exclusively on physiologic transport affect MAT-mediated substrate uptake, release, or both were modes (without any deviation from an alternating access mecha- recently discovered. Their modes of action have not yet been nism). The model posits cooperative substrate and Na1 binding and explained in a unified framework. Here, we go beyond compet- functional selectivity by conformational selection (i.e., preference of itive inhibitors and classic amphetamines and introduce con- the allosteric modulators for the substrate-loaded or substrate-free cepts for partial efficacy at and allosteric modulation of MATs.
    [Show full text]
  • Ageing, Sex and Cardioprotection Marisol Ruiz-Meana1,2, Kerstin Boengler3, David Garcia-Dorado1,2, Derek J
    Kaambre Tuuli (Orcid ID: 0000-0001-5755-4694) Kararigas Georgios (Orcid ID: 0000-0002-8187-0176) Ageing, sex and cardioprotection Marisol Ruiz-Meana1,2, Kerstin Boengler3, David Garcia-Dorado1,2, Derek J. Hausenloy4,5,6,7,8,9, Tuuli Kaambre10, Georgios Kararigas11,12, Cinzia Perrino13, Rainer Schulz3, Kirsti Ytrehus14. 1 Hospital Universitari Vall d’Hebron, Department of Cardiology. Vall d’Hebron Institut de Recerca (VHIR).Universitat Autonoma de Barcelona, Spain. 2 Centro de Investigación Biomédica en Red-CV, CIBER-CV, Spain. 3Institute of Physiology, Justus-Liebig University Giessen. Giessen 35392, Aulweg 129, Germany. 4Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore. 5National Heart Research Institute Singapore, National Heart Centre, Singapore. 6Yong Loo Lin School of Medicine, National University Singapore, Singapore. 7The Hatter Cardiovascular Institute, University College London, London, UK. 8The National Institute of Health Research University College London Hospitals Biomedical Research Centre, Research & Development, London, UK. 9Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico. 10Laboratory of Chemical Biology, National Institute of Chemical Physics and Biophysics, Akadeemia tee 23, 12618 Tallinn, Estonia. 11Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 12DZHK (German Centre for Cardiovascular Research), partner site Berlin,
    [Show full text]
  • Full-Text PDF (Final Published Version)
    Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology, 174, S208-S224. https://doi.org/10.1111/bph.13880 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13880 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13880 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology (2017) 174, S208–S224 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors Stephen PH Alexander1, John A Cidlowski2, Eamonn Kelly3, Neil V Marrion3, John A Peters4, Elena Faccenda5, Simon D Harding5,AdamJPawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical
    [Show full text]
  • Insights Into Nuclear G-Protein-Coupled Receptors As Therapeutic Targets in Non-Communicable Diseases
    pharmaceuticals Review Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases Salomé Gonçalves-Monteiro 1,2, Rita Ribeiro-Oliveira 1,2, Maria Sofia Vieira-Rocha 1,2, Martin Vojtek 1,2 , Joana B. Sousa 1,2,* and Carmen Diniz 1,2,* 1 Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; [email protected] (S.G.-M.); [email protected] (R.R.-O.); [email protected] (M.S.V.-R.); [email protected] (M.V.) 2 LAQV/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal * Correspondence: [email protected] (J.B.S.); [email protected] (C.D.) Abstract: G-protein-coupled receptors (GPCRs) comprise a large protein superfamily divided into six classes, rhodopsin-like (A), secretin receptor family (B), metabotropic glutamate (C), fungal mating pheromone receptors (D), cyclic AMP receptors (E) and frizzled (F). Until recently, GPCRs signaling was thought to emanate exclusively from the plasma membrane as a response to extracellular stimuli but several studies have challenged this view demonstrating that GPCRs can be present in intracellular localizations, including in the nuclei. A renewed interest in GPCR receptors’ superfamily emerged and intensive research occurred over recent decades, particularly regarding class A GPCRs, but some class B and C have also been explored. Nuclear GPCRs proved to be functional and capable of triggering identical and/or distinct signaling pathways associated with their counterparts on the cell surface bringing new insights into the relevance of nuclear GPCRs and highlighting the Citation: Gonçalves-Monteiro, S.; nucleus as an autonomous signaling organelle (triggered by GPCRs).
    [Show full text]
  • Modulatory Roles of ATP and Adenosine in Cholinergic Neuromuscular Transmission
    International Journal of Molecular Sciences Review Modulatory Roles of ATP and Adenosine in Cholinergic Neuromuscular Transmission Ayrat U. Ziganshin 1,* , Adel E. Khairullin 2, Charles H. V. Hoyle 1 and Sergey N. Grishin 3 1 Department of Pharmacology, Kazan State Medical University, 49 Butlerov Street, 420012 Kazan, Russia; [email protected] 2 Department of Biochemistry, Laboratory and Clinical Diagnostics, Kazan State Medical University, 49 Butlerov Street, 420012 Kazan, Russia; [email protected] 3 Department of Medical and Biological Physics with Computer Science and Medical Equipment, Kazan State Medical University, 49 Butlerov Street, 420012 Kazan, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-843-236-0512 Received: 30 June 2020; Accepted: 1 September 2020; Published: 3 September 2020 Abstract: A review of the data on the modulatory action of adenosine 5’-triphosphate (ATP), the main co-transmitter with acetylcholine, and adenosine, the final ATP metabolite in the synaptic cleft, on neuromuscular transmission is presented. The effects of these endogenous modulators on pre- and post-synaptic processes are discussed. The contribution of purines to the processes of quantal and non- quantal secretion of acetylcholine into the synaptic cleft, as well as the influence of the postsynaptic effects of ATP and adenosine on the functioning of cholinergic receptors, are evaluated. As usual, the P2-receptor-mediated influence is minimal under physiological conditions, but it becomes very important in some pathophysiological situations such as hypothermia, stress, or ischemia. There are some data demonstrating the same in neuromuscular transmission. It is suggested that the role of endogenous purines is primarily to provide a safety factor for the efficiency of cholinergic neuromuscular transmission.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • NADPH Oxidases (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F993/2019.4 NADPH oxidases (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Albert van der Vliet1 1. University of Vermont, USA Abstract The two DUOX enzymes were originally identified as participating in the production of hydrogen peroxide as a pre-requisite for thyroid hormone biosynthesis in the thyroid gland [6]. NOX enzymes function to catalyse the reduction of molecular oxygen to superoxide and various other reactive oxygen species (ROS). They are subunits of the NADPH oxidase complex. Contents This is a citation summary for NADPH oxidases in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version.
    [Show full text]
  • Sex Steroids Regulate Skin Pigmentation Through Nonclassical
    RESEARCH ARTICLE Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors Christopher A Natale1, Elizabeth K Duperret1, Junqian Zhang1, Rochelle Sadeghi1, Ankit Dahal1, Kevin Tyler O’Brien2, Rosa Cookson2, Jeffrey D Winkler2, Todd W Ridky1* 1Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 2Department of Chemistry, University of Pennsylvania, Philadelphia, United States Abstract The association between pregnancy and altered cutaneous pigmentation has been documented for over two millennia, suggesting that sex hormones play a role in regulating epidermal melanocyte (MC) homeostasis. Here we show that physiologic estrogen (17b-estradiol) and progesterone reciprocally regulate melanin synthesis. This is intriguing given that we also show that normal primary human MCs lack classical estrogen or progesterone receptors (ER or PR). Utilizing both genetic and pharmacologic approaches, we establish that sex steroid effects on human pigment synthesis are mediated by the membrane-bound, steroid hormone receptors G protein-coupled estrogen receptor (GPER), and progestin and adipoQ receptor 7 (PAQR7). Activity of these receptors was activated or inhibited by synthetic estrogen or progesterone analogs that do not bind to ER or PR. As safe and effective treatment options for skin pigmentation disorders are limited, these specific GPER and PAQR7 ligands may represent a novel class of therapeutics. DOI: 10.7554/eLife.15104.001 *For correspondence: ridky@mail.
    [Show full text]
  • Hyperlinking from BJP Articles to the Guide to PHARMACOLOGY
    Hyperlinking from BJP articles to the Guide to PHARMACOLOGY BJP requires the authors of articles accepted for publication to hyperlink the key protein targets and ligands in their article to the corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY (http://www.guidetopharmacology.org), as shown in the example below: Introduction GABAA-ρ as designated by International Union of Pharmacology (IUPHAR) (Alexander et al., 2015) and also known as GABA-ρ or GABAC receptors, are homopentameric ligand-gated ion channels (LGIC) composed of ρ subunits. They are members of the pentameric or Cys-loop LGIC superfamily comprising excitatory cation selective receptors such as nicotinic acetylcholine receptors, 5-HT3 receptors and zinc-activated channels, and inhibitory anion-selective receptors such as GABAA receptors, strychnine-sensitive glycine receptors and invertebrate glutamate- gated chloride channels (Thompson et al., 2010; Baenziger and Corringer, 2011). Receptors of this superfamily require five subunits to assemble a single ion channel. The ion channel may be homomeric formed by five identical subunits as is the case of GABA-ρ receptors, or heteromeric, consisting of a combination of at least two different subunits, such as GABAA receptors (Olsen and Sieghart, 2009). Hyperlinks Only key targets and ligands should be hyperlinked, and they should only be hyperlinked at the first mention of them in the main text. Please also create a list of the hyperlinks applied to your article in a separate word file. Please choose ‘Data Files’ as the File Designation when you upload the word file and ensure the name of the file is ‘List of Hyperlinks for Crosschecking’.
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Download Download
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F4/2019.4 Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Katrin Altosaar1, Poornima Balaji2, Richard A. Bond3, David B. Bylund4, Susanna Cotecchia5, Dominic Devost6, Van A. Doze7, Douglas C. Eikenburg8, Sarah Gora6, Eugénie Goupil6, Robert M. Graham2, Terry Hébert6, J. Paul Hieble9, Rebecca Hills10, Shahriar Kan6, Gayane Machkalyan6, Martin C. Michel11, Kenneth P. Minneman12, Sergio Parra3, Dianne Perez13, Rory Sleno6, Roger Summers14 and Peter Zylbergold6 1. Boehringer Laboratories, LLC, USA 2. Victor Chang Cardiac Research Institute, Australia 3. University of Houston, USA 4. University of Nebraska, USA 5. Université de Lausanne, Switzerland 6. McGill University, Canada 7. University of North Dakota, USA 8. University of Houston College of Pharmacy, USA 9. GlaxoSmithKline, USA 10. University of Edinburgh, UK 11. Johannes Gutenberg University, Germany 12. Emory University, USA 13. Cleveland Clinic Lerner Research Institute, USA 14. Monash University, Australia Abstract The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [58], see also [180]. Adrenoceptors, α1 α1-Adrenoceptors are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. phenylephrine, methoxamine and cirazoline are agonists and prazosin and cirazoline antagonists considered 3 125 selective for α1- relative to α2-adrenoceptors. [ H]prazosin and [ I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bodipy PLprazosin- QAPB) are used to examine cellular localisation of α1-adrenoceptors. Selective α1- adrenoceptor agonists are used as nasal decongestants; antagonists to treat hypertension (doxazosin, prazosin) and benign prostatic hyperplasia (alfuzosin, tamsulosin).
    [Show full text]
  • The Guide to PHARMACOLOGY Portal Downloaded from by Guest on 28 September 2021
    Features Special Feature A one-stop pharmacology shop The Guide to PHARMACOLOGY portal Downloaded from http://portlandpress.com/biochemist/article-pdf/35/1/36/3254/bio035010036.pdf by guest on 28 September 2021 Adam Pawson Most medicines are chemical substances that work by interacting with specific target proteins Joanna Sharman in the body. The International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Helen Benson Pharmacological Society (BPS) have joined forces to develop the Guide to PHARMACOLOGY (www. Elena Faccenda guidetopharmacology.org), a portal to information on the targets of licensed drugs and other (all University of Edinburgh, UK) targets of current research interest, such as those linked to human disease. Over the next 3 years, Michael Spedding with support from the Wellcome Trust, IUPHAR and BPS, the Guide to PHARMACOLOGY portal will be (Les laboratories Servier, France) expanded to cover all the targets of current licensed drugs and those with potential to be targets of and Anthony Harmar future therapeutics. Our goal is to provide scientists, doctors, allied professions and the general public (University of Edinburgh, UK) with a ‘one-stop shop’ source of information on how drugs work, and to help researchers to design experiments using the appropriate reagents. The revolution in genomics and molecular the interested public. The first version of the Guide to genetics has led to the identification of many novel PHARMACOLOGY integrates information on drug approaches to the development of new medicines. targets from two established resources: the BPS Guide However, there is an urgent need for an accessible and to Receptors and Channels (GRAC) and IUPHAR-DB.
    [Show full text]